Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy-Reference-Cited by-同舟云学术

Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy

Published:2013-11-19 Issue:10 Volume:134 Page:2437-2447
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Weller Michael¹,Kaulich Kerstin²,Hentschel Bettina³,Felsberg Joerg²,Gramatzki Dorothee¹,Pietsch Torsten⁴,Simon Matthias⁵,Westphal Manfred⁶,Schackert Gabriele⁷,Tonn Joerg C.⁸,von Deimling Andreas⁹,Davis Thomas¹⁰,Weiss William Andrew¹¹,Loeffler Markus³,Reifenberger Guido²,

Affiliation:

1. Department of Neurology; University Hospital Zurich; and Neuroscience Center Zurich Zurich Switzerland

2. Department of Neuropathology; University of Düsseldorf; Düsseldorf Germany, and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany

3. Institute for Medical Informatics; Statistics and Epidemiology, University of Leipzig; Leipzig Germany

4. Institute of Neuropathology; University of Bonn; Bonn Germany

5. Department of Neurosurgery; University of Bonn; Bonn Germany

6. Department of Neurosurgery; University of Hamburg; Hamburg Germany

7. Department of Neurosurgery; Technical University of Dresden; Dresden Germany

8. Department of Neurosurgery; Ludwig-Maximilians-University; Munich Germany

9. Department of Neuropathology; Institute of Pathology, University of Heidelberg; Heidelberg Germany

10. Celldex Therapeutics; Needham MA, USA

11. Departments of Neurology Pediatrics and Neurological Surgery USCF; San Francisco CA, USA

Publisher

Wiley

Subject